The potential role of sunitinib in gastrointestinal cancers other than GIST.

Abstract

Gastrointestinal tumors are the most frequent and lethal malignancies worldwide. The deeper knowledge in molecular biology mechanisms involved in carcinogenesis has allowed the design of new targeted drugs mainly directed against the epidermal growth factor receptor (EGFR), the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Sunitinib is an oral multitargeted inhibitor of the VEGF, platelet-derived growth factor (PDGF), and c-KIT, among others, tyrosine kinase receptors. Therefore, sunitinib acts in a dual mode as antiangiogenic agent and as antitumoral drug. The aim of this review is to gather the preclinical rationale behind the clinical use of sunitinib in gastrointestinal malignancies other than gastrointestinal stromal tumors (GIST) and to summarize the clinical data from phase I to III trials currently available.

• Authors: Cristina Grávalos, Enrique Grande, Joan Manel Gasent
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 76 Issue 1 Pg. 36-43 (Oct 2010) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 20133148 (Publication Type: Journal Article)
• Copyright: Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Indoles
• Pyrroles
• Sunitinib

Topics

• Angiogenesis Inhibitors (pharmacokinetics, pharmacology, therapeutic use)
• Animals
• Clinical Trials as Topic
• Gastrointestinal Neoplasms (drug therapy)
• Gastrointestinal Stromal Tumors (drug therapy)
• Humans
• Indoles (pharmacokinetics, pharmacology, therapeutic use)
• Pyrroles (pharmacokinetics, pharmacology, therapeutic use)
• Sunitinib